Uses
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)[1].
References
[1] Zhu C, et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol. 2020 Aug 14;11:1771. DOI:
10.3389/fimmu.2020.01771
